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REVIEW
Space-occupying brain lesions, 
trauma-related tau astrogliopathy, and ARTAG: 
a report of two cases and a literature review
Adam D. Bachstetter1,2,3* , Filip G. Garrett3,4, Gregory A. Jicha3,5 and Peter T. Nelson3,4 
Abstract 
Astrocytes with intracellular accumulations of misfolded phosphorylated tau protein have been observed in 
advanced-stage chronic traumatic encephalopathy (CTE) and in other neurodegenerative conditions. There is a 
growing awareness that astrocytic tau inclusions are also relatively common in the brains of persons over 70 years of 
age—affecting approximately one-third of autopsied individuals. The pathologic hallmarks of aging-related tau astro-
gliopathy (ARTAG) include phosphorylated tau protein within thorn-shaped astrocytes (TSA) in subpial, subependy-
mal, perivascular, and white matter regions, whereas granular-fuzzy astrocytes are often seen in gray matter. CTE and 
ARTAG share molecular and histopathologic characteristics, suggesting that trauma-related mechanism(s) may pre-
dispose to the development of tau astrogliopathy. There are presently few experimental systems to study the patho-
biology of astrocytic-tau aggregation, but human studies have made recent progress. For example, leucotomy (also 
referred to as lobotomy) is associated with a localized ARTAG-like neuropathology decades after the surgical brain 
injury, suggesting that chronic brain injury of any type may predispose to later life ARTAG. To examine this idea in a 
different context, we report clinical and pathologic features of two middle-aged men who came to autopsy with large 
(> 6 cm in greatest dimension) arachnoid cysts that had physically displaced and injured the subjects’ left temporal 
lobes through chronic mechanical stress. Despite the similarity of the size and location of the arachnoid cysts, these 
individuals had dissimilar neurologic outcomes and neuropathologic findings. We review the evidence for ARTAG in 
response to brain injury, and discuss how the location and molecular properties of astroglial tau inclusions might alter 
the physiology of resident astrocytes. These cases and literature review point toward possible mechanism(s) of tau 
aggregation in astrocytes in response to chronic brain trauma.
Keywords: Tangles, NFTs, PSP, TBI, Tauopathy, Meninges, FTLD
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Much remains unknown about astrocytes in healthy 
and diseased states. Here we discuss a specific subset of 
astrocyte pathology, related to a hypothesis that localized 
trauma can induce tau astrogliopathy, which is similar in 
appearance to age-related tau astrogliopathy (ARTAG). 
It has recently become clear that chronic traumatic 
encephalopathy (CTE) is associated with both neuronal 
and glial tau pathology [1, 2]. Further, even decades after 
neurosurgical procedures severing frontal white mat-
ter tracts (leucotomies), the frontal cortical tissue that 
was traumatically affected tended to contain astrocytes 
with abnormal tau accumulations [3]. These observations 
raised intriguing questions about human astrogliopathy 
seen commonly at autopsy, and the inter-relationships 
between brain trauma and astrocytic tau proteinopa-
thy. This review includes a presentation of two cases 
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that experienced chronic mechanical stress induced by 
large, localized, space-occupying brain lesions (arach-
noid cysts), examined for ARTAG and other pathologies. 
These case reports are followed by a broader discus-
sion of relevant scientific literature, focusing on human 
studies.
Case reports
Arachnoid cysts are non-neoplastic alterations of the 
leptomeninges resulting in a fluid-filled space between 
the brain or spinal cord and the arachnoid membrane. 
Arachnoid cysts usually arise from arachnoid mem-
brane splitting in early development, although second-
ary cysts have been reported following head trauma [4, 
5]. In adults, arachnoid cysts are often clinically silent 
and may persist for decades [6, 7]. We present clinical 
and pathologic findings from two adult males with large 
arachnoid cysts. Note that in keeping with terminology 
applied in other conditions [8, 9], we distinguish between 
ARTAG (concept and disease) and the relevant neuro-
pathologic hallmarks (ARTAG–NC); likewise for CTE 
and CTE–NC.
Case 1 A Caucasian male who was part of the Univer-
sity of Kentucky Alzheimer’s Disease Center longitudinal 
research cohort [10] came to autopsy at age 72 following 
a complex neurological history. His mother died with 
unspecified dementia, and his maternal grandmother had 
ALS. He worked in the field of clothing manufacture and 
retired at age 55. Progressive dementia was first noted 
at age 66, characterized by aggressive behavior that was 
clinically compatible with a frontotemporal syndrome. 
The subject’s history was also notable for epilepsy (com-
plex-partial seizures), type II diabetes, depression, inter-
mittent alcohol use (up to a 1L whiskey/week), and there 
was a clinical note of “post-Polio syndrome”. Reports of 
possible football-related concussions in high school were 
noted, as well as falls in late life, but more detailed infor-
mation on closed head injury and brain trauma were 
lacking in the medical and research records. Final Mini-
Mental State Examination score at age 70 was 17, final 
global clinical dementia ratings (CDR) scale score was 2, 
and final CDR “sum of boxes” = 13, indicating dementia 
of moderate severity. The patient died of acute cardio-
pulmonary arrest, unrelated to his dementia syndrome. 
Four years before death, a head computed tomography 
(CT) scan was performed as part of his seizure workup 
which revealed a large arachnoid cyst within the left tem-
poral fossa and Sylvian region (Fig.  1a). Neurosurgical 
intervention was not pursued, in favor of observation. In 
serial CT scans performed over the subsequent years, the 
cyst remained stable in size, with progressive global brain 
atrophy notably increasing over time.
On post-mortem examination, the left side of his brain 
showed a large evacuated area measuring 75 × 50 × 30 
mm (Fig. 1b). The lesion was adjacent to the left Sylvian 
fissure and resulted in extensive encroachment on the 
anterior temporal lobe, completely exposing the left mid-
dle cerebral artery from the ventral aspect (Fig.  1a, b). 
There was marked deformation and atrophy of the medial 
temporal lobe structures, and evidence for grossly appar-
ent orbitofrontal subpial hemorrhage or contusion.
Microscopic examination confirmed that the cyst lining 
comprised a delicate fibrous membrane with areas of an 
intact single layer of cells (arachnoid cells) and scattered 
foci of meningothelial cells. In the orbitofrontal cortex 
where discoloration (subpial hemorrhage) was noted on 
gross exam, the same area showed chronic degenerative 
changes including localized necrosis, neuropil rarefac-
tion, and abundant hemosiderin-laden macrophages (not 
shown). A neurodegenerative assessment revealed an 
intermediate level of Alzheimer’s disease neuropatho-
logic changes (ADNC): (Thal phase 5; Braak NFT stage 
IV; Frequent neuritic plaques). The 2012 NIA-AA con-
sensus ABC score was A = 3, B = 2, C = 3. In addition, 
immunohistochemical stain for aberrantly hyperphos-
phorylated tau proteins (PHF-1 antibody [11]) displayed 
features of both CTE–NC (Fig.  2) and ARTAG–NC 
(Fig.  3). The CTE–NC-like changes included patchy 
distribution of neuronal PHF-1+ tau at sulcal depths 
of the cerebral cortex (Fig.  2). Several cerebrovascular 
pathologies were also identified, including small chronic 
ischemic infarcts.
While CTE–NC-like intraneuronal tauopathy was 
observed focally, the ARTAG–NC-like pathology was 
more extensive (Fig.  3). Numerous TSAs were seen 
within the white matter of the neocortex (frontal, tempo-
ral and parietal lobe) and the medial temporal lobe struc-
tures (amygdala, entorhinal cortex, and hippocampus). 
Many TSAs were present subjacent to the pia mater. The 
cortical regions adjacent to the arachnoid cysts showed 
prominent astrocytic tau accumulation arranged along 
small vessels at the depth of the sulci (Fig. 3d). The distri-
bution and proximity of the CTE–NC and ARTAG–NC 
to the arachnoid cysts raised the question of whether this 
large space-occupying lesion induced the tau proteinopa-
thy through chronic mechanical stress.
Case 2 A Caucasian male was evaluated post-mortem 
by the University of Kentucky Pathology Department at 
age 64. He had previously been employed at a commer-
cial nursery and used spray insecticides regularly on the 
job but retired before age 40. There was no known family 
history of dementia. Medical records indicated the pres-
ence of a “congenital” arachnoid cyst. His medical history 
was otherwise complex. He underwent a double lung 
transplant at age 57 years due to idiopathic pulmonary 
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fibrosis, and was on tacrolimus. He had advanced liver 
disease with biopsy-diagnosed sarcoidosis, chronic CMV 
viremia (taking valacyclovir 900 mg twice daily) and 
rheumatoid arthritis treated with chronic steroids. At age 
54, he “sustained a right-sided intracranial hemorrhage” 
and reportedly underwent craniotomy and surgical 
evacuation that left him with a partial facial hemiplegia. 
The arachnoid cyst was visualized at the University of 
Kentucky radiographically (shown in Fig.  1c) at age 56. 
Neurosurgical intervention was not pursued, in favor of 
observation. Serial CT scans performed at ages 58 and 62 
years showed that the cyst remained stable in size. At age 
60, he was seen by Neurology for parkinsonism, which 
was attributed to a medication (metoclopramide) side-
effect. Concerns were raised about short-term memory 
loss at that evaluation, but cognitive impairment was 
Fig. 1 Clinical (premortem) computerized tomography (CT) scans, and photographs of brain after autopsy and fixation, in two cases with large 
arachnoid cysts. Case #1 is a male, 72 years old at death. This CT scan (a) was acquired at age 68. (b) The brain at autopsy following fixation from 
Case #1 shows the large left-sided arachnoid cyst cavity. Both the anterior temporal lobe and the orbitofrontal frontal lobe are affected by the 
lesion. Note that on the surface of the frontal cortex within the cyst cavity there is discoloration (white arrow). By contrast, the right side lacks 
evidence of indentation or contusion in the orbitofrontal cortex. Case #2 is a male, 64 years old at death. The CT scan (c) was acquired at age 56. 
As seen in the brain at autopsy following fixation (d), the arachnoid cyst is larger in the rostral-caudal axis in Case #2 in comparison to that of Case 
#1. However, the lesion is shallower—the affected region is smaller in the dorsal–ventral axis, and there was less impact on the orbitofrontal cortex 
(black arrow) in Case #2 compared to Case #1
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never formally diagnosed. No other salient neurological 
symptoms were noted in the medical record review.
On post-mortem examination, the brain showed 
an evacuated area on the left side measuring 
80 × 35 × 30 mm (Fig. 1c, d). Compared to the arachnoid 
cyst seen in Case #1, this lesion did not appear as impact-
ful on the orbitofrontal cortex, but still caused significant 
distortion of the temporal lobe. Microscopic examination 
confirmed the arachnoid nature of the cyst and revealed 
severe, widespread small vessel disease, including arte-
riolosclerosis, widening of the Virchow–Robin spaces, 
and perivascular pigment-laden macrophages. Sections 
sampled from near the arachnoid cyst were negative for 
AD–NC (neurofibrillary tangles and neuritic plaques); 
however, scant p-tau immunoreactive structures were 
focally present within the medial temporal lobe (Fig. 4). 
The p-tau immunoreactivity was seen adjacent to the 
ependymal lining of the lateral ventricle (inferior horn) 
(Fig.  4a) and occasionally surrounding Virchow–Robin 
spaces of the parenchymal arterioles (Fig. 4b).
Literature review: astrocytes, brain injury, and tau 
protein
Clinical and biologic features of Cases #1 and #2 relate 
to three research domains: astrocytes; the sequelae of 
chronic mechanical stress and brain trauma; and tau 
pathobiology. Astrocytes are the most numerous cell 
type in the CNS, serving fundamental roles in support 
of brain function and regulating brain energy metabo-
lism [12, 13]. Astrocytes also sustain synaptic activity and 
homeostasis [14], and contribute to CNS inflammatory 
signaling [15, 16]. The astrocyte glia limitans is a critical 
anatomic domain at the blood–brain-barrier and at the 
interface with the meninges [17]. Astrocytes also help 
remove cellular waste via glymphatic flow [18]. Given the 
many necessary functions of astrocytes in CNS physiol-
ogy, astrocytic failure may contribute to synaptic dys-
function, neuronal loss, and neurodegeneration through 
a number of biologic mechanisms [19–21].
Astrogliopathy is a term used to describe a spectrum 
of astrocyte changes associated with injury or disease. 
Astrogliopathy can be divided into reactive astrogliosis or 
astrocytopathy [22], with the caveat that neither of these 
processes are thoroughly understood. The term reactive 
astrogliosis refers to astrocytic responses to changes in the 
environment. Following brain injury, reactive astrogliosis 
walls off the area of injury creating a functional border 
(“glial scar”) limiting molecular infiltration and recruit-
ment of immune cells into the parenchyma [17]. With 
the proliferation of astrocytes and a loss of the astrocyte 
domain structure, a glial scar is an extreme example of a 
reactive astrocyte change, whereas many different altera-
tions in brain physiology or disease may cause a milder 
reactive astrogliosis [22]. Reactive astrogliosis is typically 
both neuroprotective and reversible [22].
Astrocytopathy, in contrast, is a term which describes 
degenerative remodeling of astrocytes, and is linked to 
many different brain diseases. For example, Alexander’s 
disease is a primary astrocytopathy caused by the over-
expression of the intermediate filament glial fibrillary 
acidic protein (GFAP) [22]. Although primarily linked to 
an astrocytic protein overexpression, Alexander’s disease 
is associated with misfolding of at least one other pro-
tein—TDP-43 [23]. ARTAG and severe (advanced-stage) 
CTE are astrocytopathies characterized by astrocytic tau 
inclusions.
Fig. 2 CTE-like neuronal pathology in frontal cortex (middle frontal gyrus) of Case #1. (a) Low magnification of H&E-stained section shows the 
location (white box) of the CTE-like perivascular cluster of phosph-tau (p-tau) illustrated in adjacent PHF1 + stained section (b). A single cluster of 
PHF-1 + staining seen in the depth of the cortical sulci (B, black arrow). (c) At a higher magnification the large vessel (black arrow) is surrounded by 
p-tau + neuronal and astrocyte staining
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The normal functions of tau protein are debated [24–
26] and the roles for tau proteins in glial cells are mostly 
unknown. In the adult human brain, six tau isoforms 
are generated by alternative splicing of the microtubule 
associated protein tau (MAPT) gene. Depending on 
whether the proteins contain three or four carboxy-ter-
minal tubulin-binding domains (“repeats”), the proteins 
can be classified as 3R or 4R tau, respectively [27, 28]. 
Immunohistochemical studies showed that astrocytes in 
ARTAG–NC and CTE–NC are negative for 3R tau and 
positive for 4R tau [29, 30].
To date, ARTAG–NC has not been reported in ani-
mal models in response to injury [31]. Yet it must be 
emphasized that rodents do not develop tauopathy in 
aging as humans do [32], and studies of genetically modi-
fied rodent models have primarily focused on neuronal 
tau [31]. The lack of astroglial tauopathy was mostly 
Fig. 3 Phospho-tau (p-tau) immunohistochemistry in the left fronto-parietal region of Case 1. In the low-magnification photomicrograph (a), the 
pia mater is near the bottom and white matter (WM) near the top. This is a section of the left fronto-parietal cortex, which is caudal to the region 
most directly impacted by the arachnoid cyst, and shows widespread p-tau (PHF-1) immunoreactivity in the subpial, gray matter, and white matter 
regions. In each of these compartments there is prominent staining of p-tau surrounding small blood vessels, and also in cells with morphologic 
features of astrocytes. Subpial staining is demonstrated in a small sulcus (b) and additional subpial staining is shown at low power in the adjacent 
gyrus (blue arrow in a). (c) White matter shows p-tau cells with astrocyte morphology, as well as staining around blood vessels resembling 
astrocyte foot processes (blue arrow). (d) The astrocytic p-tau in gray matter highlight pericapillary staining (blue arrows); the inset shows compact 
p-tau + cells with astrocyte features (e)
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described in engineered mice with human tau transgenes 
driven by neuron-specific promotors that develop solely 
neuronal rather than glial tau inclusions. The animal 
models’ inability to recapitulate human tau changes in 
response to brain injury could also be due to species dif-
ference in the native tau protein sequence, and/or kinases 
that contribute to the development of a tau astrogliopa-
thy, as well as species differences in brain size and struc-
ture [33–36]. Thus, despite the similarities between the 
astroglial tau inclusions seen in CTE and ARTAG, there 
are few experimental model systems to study the pathol-
ogy. The human phenomenology of tau astrogliopathies 
(as in other diseases) will likely prove informative. A goal 
of the present review is to discuss the relevant observa-
tions in human brains, that may aid in the development 
of mechanistic hypotheses for the development of tau 
astrogliopathy.
Inter‑relationships between CTE and ARTAG: 
evolving concepts
Associated with repetitive head injuries, CTE was first 
studied in boxers as dementia pugilistica or “punch-
drunk syndrome”, with subsequent research on American 
football players and other elite athletes engaged in con-
tact sports where closed head injury is common [37, 38]. 
According to the current criteria, the CTE–NC pathog-
nomonic lesion is p-tau+ neurofibrillary tangles sur-
rounding small blood vessels, in a patchy distributions 
at sulcal depths of the cerebral cortex [2, 39]. CTE–NC 
requires the presence of p-tau immunoreactive neurons 
with or without p-tau immunoreactive astrocytes; how-
ever, these lesions commonly coexist [2, 39, 40]. The 
distribution of tau pathology in CTE–NC and ARTAG–
NC suggests some shared etiology [41–43]. Further, the 
presence of tau pathology in astrocytes in cases with 
CTE–NC suggests that ARTAG–NC could be a response 
of astrocytes to chronic mechanical stress or repetitive 
acute traumatic brain injury [1, 2, 43].
Whether a single moderate-to-severe TBI leads to 
CTE–NC is debated [1, 44–47]. Arena et  al. [1] evalu-
ated a series of cases with CTE–NC for astroglial tau 
and compared those cases to other tauopathies includ-
ing ARTAG, AD, corticobasal degeneration (CBD), pri-
mary age-related tauopathy (PART), Pick’s disease (PiD), 
and progressive supranuclear palsy (PSP). Astrocyte tau 
in CTE–NC shared molecular properties with ARTAG 
cases. That is, the p-tau+ astrocytes expressed only 4R 
tau, similar to ARTAG-p-tau+ astrocytes, while neurons 
in CTE express both 3R and 4R tau, similar to AD [43]. 
Cherry et al. [48] examined 99 cases of CTE–NC for the 
presence of 3R and 4R tau. Neurons expressed both 3R 
and 4R tau pathology, while astrocytes only expressed 
4R tau pathology. However, astrocyte tau changes were 
only found in the more advanced (Stage III/IV) CTE–NC 
cases. Intriguingly, p-tau+ astrocytes increased with age. 
A tipping point was seen in the sixth decade of life, with 
the percentage of p-tau+ astrocytes increasing linearly 
into the seventh and eight decade of life, at which point 
astrocytes accounted for at least 50% of the 4R tau+ cells 
in the perivascular lesions [48]. Many questions remain 
Fig. 4 Sparse glial phospho-tau (p-tau) immunohistochemistry in Case 2. In this case, p-tau (PHF-1) immunoreactive structures were much 
more sparse, mostly non-neuronal, and were apparent in the medial temporal lobe. (a) In the hippocampus, p-tau immunostaining was found 
surrounding the rostral fringe of the inferior horn of the lateral ventricle (blue arrows; the ependymal lining denoted with an asterisk). Note that 
a few TSAs are stained (e.g., magenta arrow). (b) Shows p-tau immunoreactivity surrounding Virchow–Robin spaces of arterioles (blue arrow). 
Scattered p-tau + cells with delicate glial processes were also observed, such as that shown in (c) from the left-sided temporal cortex
Page 7 of 15Bachstetter et al. acta neuropathol commun            (2021) 9:49  
about the importance of intrinsic (including genetic) 
factors, injury physics, and the how idiosyncratic sin-
gle-trauma (TBI) and multiple/repetitive trauma (CTE) 
conditions relate to these findings.
As awareness grows of CTE and its public health 
impact, case reports and cohort studies have accumu-
lated outside the realm of contact sports [49–53]. These 
have included subjects with trauma from reported falls, 
vehicular accidents, military service, and other injuries 
that are independent of sports-related injuries. Inter-
estingly, much of the reported pathology in such cases 
appears to be ARTAG–NC—perivascular p-tau+ astro-
cytes. However, there are also examples of p-tau+ neu-
rofibrillary tangles at sulcal depths of the cerebral cortex 
in non-sports related CTE [2, 53].
In the two current cases with large arachnoid cysts, 
the individual (Case #1) with ARTAG–NC and CTE–NC 
like pathology had prior history of playing contact sports 
with documented concussions. In contrast, the person 
without ARTAG–NC or CTE–NC pathology (Case #2) 
had no known history of contact sports or TBI. These 
results support the connection between TBI and ARTAG 
but also suggest that TBI is not the sole driver of the 
ARTAG–NC seen in these cases. We cannot rule out that 
the nature of the arachnoid cyst in Case #1 was deeper 
and therefore itself caused added chronic mechani-
cal stress related injury to the brain, as indicated by the 
bruising along the cyst cavity (Fig. 1). This hypothesis is 
supported by the findings of minimal/incipient ARTAG–
NC in Case #2, that also demonstrated chronic mechani-
cal stress related injury to the brain, without a history of 
acute TBI or closed head injury (Fig. 1).
The community-based autopsy study by Forrest et  al. 
[54] provided insights into the prevalence of CTE and 
ARTAG in a high-quality European cohort. This study 
included 310 individuals aged 76-91 years old and evalu-
ated multiple brain regions for the presence of CTE–NC 
and ARTAG–NC. One-third of the cases in this cohort 
were found to have ARTAG–NC. The findings of a 
very substantial proportion of elderly brains harbor-
ing ARTAG–NC are consistent with results from other 
community-based and clinic-based autopsy cohorts [30, 
55–57]. It was also described that neocortical, as opposed 
to limbic or brainstem ARTAG–NC, was most strongly 
associated with dementia status [57].
Forrest et  al. went on to explore the connection 
between a reported history of TBI and ARTAG–NC 
[54]. Of the 310 people included in the study, 67 people 
Fig. 5 Illustration of morphology and location of aging-related tau astrogliopathy neuropathological changes (ARTAG–NC). (a) Phosphorylated 
tau protein (p-tau) immunopositive astrocytes can broadly be found in five parts of the brain. (The illustration is not meant to be specific for any 
neuroanatomical region of the brain). TSAs are seen in the border-associated astrocytes of the subpial (b) and subependymal borders (c) (location of 
C not shown on A). (d) Perivascular astrocytes are the third border associated TSA. (It is not yet defined if these are exclusively arterial or are also venous 
associated astrocytes). (e) TSAs are also seen in the white matter. (f) In the gray matter, GFAs are the second disease-defining astrocyte morphology
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completed a self-reported TBI questionnaire. Only six 
subjects reported a loss of consciousness for at least 10 
minutes (this number may reflect an underreporting 
or recall bias). If a single brain trauma caused ARTAG, 
ARTAG–NC would be expected in those six cases. How-
ever, only two of six cases with documented TBI were 
found to have ARTAG–NC—the same 1/3rd proportion 
as in the cohort overall. These results support the null 
hypothesis and underscore that more data is required 
about the relationship between clinical TBI history and 
ARTAG neuropathology.
In a novel approach to the study of brain trauma, Shively 
et al. [3] examined the brains of five individuals who under-
went surgical leucotomy at least 40 years prior to death. The 
leucotomized subjects were schizophrenics and the study 
included matched subjects with schizophrenia that did not 
have leucotomy [3]. Thus, they controlled for severity, time, 
and location of the brain injury, while avoiding some of the 
recall bias inherent to sports and TBI studies.
In the leucotomy cases, as expected, pathological 
evaluation showed severe, localized white matter dam-
age. CTE–NC was also present in some cases, including 
p-tau in neurons in cortical sulcal depths and around 
small blood vessels [3]. However, the dominant pathology 
was ARTAG–NC-like changes (astrocyte p-tau) and 
not neuronal CTE–NC pathology. The matched con-
trol cases lacked ARTAG–NC or CTE–NC changes [3]. 
Around the surgical lesion in the white matter, a dense 
astroglial scar was present along with subpial astrocyto-
sis at the proximal depth of the overlying cortical tissue’s 
sulci. Despite the severity of the subcortical white matter 
injury in the leucotomy cases, the gray matter was rela-
tively intact; and cortical astrogliosis was absent. We note 
that Okamura et al. [58] also reported neuronal and glia 
p-tau pathology in 2 Japanese cases following leucotomy 
and provided a summary of previous neuropathological 
evaluations of leucotomy cases [58].
Shively et  al. [3] tested whether tauopathy in astro-
cytes was a predictable component of glial scars or is a 
more idiosyncratic degeneration of a subset of astrocytes. 
Using serial sections, they stained for GFAP+ astro-
gliosis and p-tau. Despite the dense GFAP+ staining in 
the white matter adjacent to the cystic space-occupying 
lesion border, there was no p-tau staining in adjacent 
serial sections [3]. The lack of neuronal or astrocyte p-tau 
is informative as it shows that ARTAG–NC is not sim-
ply an unselective response to injury. Moreover, p-tau+ 
astrocytes were seen at the pia surface in depths of the 
Fig. 6 Comparison of white matter fibrous versus tau + thorn-shaped astrocytes. A summary of the molecular characteristics of healthy white 
matter fibrous astrocytes is shown in comparison to reported changes in white matter thorn-shaped astrocytes. The text highlighted in red are 
known changes in the thorn-shaped astrocytes in ARTAG 
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sulci. In contrast to the intense astrogliosis seen at the 
border of the cystic space-occupying lesion, where 
ARTAG–NC was not seen, the subpial ARTAG–NC pos-
itive regions demonstrated only limited GFAP+ astro-
gliosis [3]. This suggests that astrogliosis alone was not 
the primary cause of ARTAG–NC. There must be other 
contributing factors, which may be specific to particular 
anatomic microdomains.
Shively et  al. [3] suggested two hypotheses for the 
neuropathologic changes seen in their study. The first 
hypothesis was that axonal injury was the cause of the 
lesions. In the second hypothesis, the sulcal depths were 
more vulnerable to mechanical stress caused by the leu-
cotomy procedure. Similar arguments for mechanical 
stress at sulcal depths have been proposed for CTE. The 
authors, however, stated their data supported the first 
hypothesis that the p-tau accumulation resulted from 
axonal damage. They further suggested that the accumu-
lation of perivascular tau and the tau in the sulcal depths 
might be associated with the clearance of tau from the 
brain. They proposed that these locations were consistent 
with tau clearance via a glymphatic flux [3]. That is, the 
p-tau accumulation in the perivascular space and sulcal 
depths amounted to a ring around the drain as tau left the 
brain from injured axons. In our current case studies, it is 
notable that the arachnoid cyst in Case #2 caused long-
term deformity of the brain, with far milder ARTAG–
NC, underscoring that additional factors (intrinsic and 
environmental) may play important roles.
Distinct populations of p‑tau + astrocytes
Astrocytic tau inclusions are not only seen in ARTAG. 
Indeed, astrocytic tau changes can be a cardinal neu-
ropathologic (if not pathognomonic) lesion in primary 
tauopathies, including tufted astrocytes in PSP, astro-
cytic plaques in CBD, globular astroglial inclusions in 
GGT, and ramified astrocytes in PiD [41, 42, 59]. Astro-
cytic tau changes in these primary tauopathies differ in 
morphology and location from those seen in ARTAG–
NC. Importantly, as described in our case reports, there 
are subregions of the brain that appear more vulnerable 
towards the development of ARTAG–NC. Therefore, 
to understand possible causes of ARTAG–NC and how 
ARTAG–NC might alter brain physiology, it is important 
to appreciate the heterogeneity of ARTAG–NC.
ARTAG–NC may include three populations of border-
associated astrocytes, as well as protoplasmic gray matter 
and fibrous white matter astrocytes (Fig.  5). The astro-
cytes’ morphologic appearance defines the cells as TSA 
and GFA. In CTE and in response to brain injury, much 
of the ARTAG–NC is TSA. However, a different picture 
may be seen in neurodegenerative disease. Notably, indi-
viduals defined as healthy controls lacked gray matter 
ARTAG–NC, while 32% of AD/PART cases and 37% of 
Lewy body dementia cases had gray matter ARTAG–NC 
[60]. These results do not rule out the involvement of 
brain trauma as a contributor to ARTAG–NC. They do 
suggest that there may be heterogeneity among ARTAG 
subtypes, and it is important to consider differences in 
location and type of ARTAG–NC found.
As shown in Fig. 5, TSAs may be found in three border 
region-associated astrocytes, and some of the morpho-
logical features are shared across the different anatomi-
cal regions. This includes the TSA astrocytes at the 
subpial (Figs. 3b, 5b) and subependymal border (Fig. 5c). 
In these locations, the astrocyte processes of the TSAs 
reach the outer surface of the brain (Fig. 5b) or the cen-
tral ependyma lining the ventricles (Fig. 5c). The subpial 
TSAs are likely marginal astrocytes, also known as inter-
laminar astrocytes. These are a relatively poorly studied 
population of specialized glia that form layers of end-
feet at the pial surface, thus forming the glia limitans in 
the brain-meninges border. In humans, these marginal 
astrocytes send long, thin projections into the deeper 
cortical layers terminating in cortical layers II through 
IV [61]. Subpial TSAs are most often found in the cer-
ebral cortical lobes, amygdala, hippocampus, basal fore-
brain, lateral midbrain, pons, medulla oblongata, and 
into the spinal cord [60]. Subependymal TSAs are seen 
in the third ventricle, the inferior horn of the lateral ven-
tricle, aqueduct of the midbrain and medulla oblongata, 
and rarely in the anterior and posterior horn of the lat-
eral ventricle [60].
The third border-associated ARTAG-vulnerable astro-
cytes are perivascular (Fig.  5d). The perivascular TSAs 
can be seen near the subpial surface, or in gray (Fig. 3e) 
or white matter (Fig.  3c) [60]. Subpial, subependymal, 
and perivascular astrocytes maintain blood-brain and 
brain-CSF-blood barriers, and regulate glymphatic flow 
[18]. If perivascular ARTAG–NC was abundant in the 
venous compartment, this could suggest a role in the 
movement of CSF and drainage out of the brain, whereas, 
if the perivascular ARTAG–NC was extensively in the 
arterial compartment, this could impact cerebral blood 
flow autoregulation. We identified ARTAG–NC sur-
rounding Virchow–Robin spaces of arterioles (Fig.  4b) 
and surrounding capillaries in the cortex (Fig. 3d). Prior 
studies emphasized that ARTAG–NC can be found in the 
arterial compartment [41, 60]. More work is needed to 
evaluate ARTAG–NC associated with different cerebral 
vascular segments quantitatively, and if trauma versus 
neurodegenerative pathology causes a different vascular 
localization pattern.
White matter is another compartment where TSAs are 
found in ARTAG (Figs.  5e, 6). The white matter of the 
medial temporal lobe has the highest likelihood of TSA, 
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whereas the occipital lobe is the least likely [62]. Interest-
ingly, the white matter of the corpus callosum, internal 
capsule, or cerebellar peduncles tend to be unaffected by 
ARTAG–NC [60]. The physiology of white matter fibrous 
astrocytes are poorly understood in healthy and disease 
states. By morphology, the fibrous astrocytes of the white 
matter have fewer branches than the gray matter astro-
cytes. The fibrous astrocytes align radially in the direc-
tion of the axonal tracks. These astrocytes also lack the 
tiling properties of gray matter astrocytes [61].
GFAs found in the gray matter are present most often 
in the amygdala, basal ganglia, cortex, and brainstem [63] 
(Fig. 5f ). As the name suggests, GFAs have a fine granu-
lar appearance by p-tau-immunostaining, that appears to 
fill the cytoplasm of the protoplasmic astrocytes in the 
gray matter. GFAs have been found to be the most preva-
lent type of ARTAG–NC [54]. Further clues suggest that 
gray matter GFAs could be one of the earliest pathologi-
cal changes associated with ARTAG–NC [54, 60, 62]. In 
our cases, GFAs were not widely observed in the cortical 
gray matter (Fig. 3d), suggesting that TSAs may be more 
specific to trauma, while GFAs could be associated with 
neurodegenerative pathology.
Tau expression and protein modifications relevant 
to ARTAG 
Little is known about tau expression (either transcription, 
or translation from mRNA) within human astrocytes. Via 
tubulin-binding domains, tau proteins may interact with 
microtubules, which are certainly present in astrocytes. 
Yet as far as we know, non-phosphorylated tau protein 
has not been visualized in quiescent astrocytes.
At least three studies reported single-cell or single-
nuclei RNAseq data on human brain tissue suitable for 
studying MAPT transcripts in astrocytes. Their results 
were highly similar with each other in some impor-
tant ways (Fig.  7). The first study conducted single-cell 
RNAseq on adult temporal cortex from individuals 
undergoing surgery for refractory seizures [64] (Fig.  7a, 
b). Using the authors’ cell type clusters, most astrocytes 
(77%) had low or nearly undetectable levels of MAPT. 
In comparison, 37% of neurons and 61% of oligodendro-
cytes had low or nearly undetectable levels of MAPT. 
On average, astrocytes expressed 67% less MAPT than 
neurons. Approximately a quarter of astrocytes express 
MAPT transcripts, and, notably, this population(s) of 
astrocytes express MAPT at similar levels to that of 
neurons. The second study completed single-nucleus 
RNAseq from the postmortem prefrontal cortex of 17 
healthy control males as part of a study on major depres-
sive disorder [65] (Fig. 7c, d). In these individuals, 75% of 
astrocytes expressed no MAPT. Yet, the astrocytes that 
did express MAPT again did so at comparable levels to 
neurons. The third study performed single-nucleus RNA 
sequencing from the postmortem entorhinal cortex of 
six AD patients and six sex- and age-matched controls 
[66] (Fig.  7e–g). Once again, approximately 3/4th of the 
astrocytes did not express MAPT. Similarly, in the AD 
brain, 74% of the astrocytes did not express MAPT. In 
the astrocytes that did express MAPT transcripts, there 
was a significant (p < 0.001) increase in MAPT expression 
in the AD cases compared to control cases.
Fig. 7 MAPT (Tau mRNA transcript) expression in astrocytes from 
human adult brain. Shown are results from three different single-cell 
and single-nucleus RNAseq studies (from outside laboratories) which 
analyzed mRNA transcripts in human brain samples. Pie charts (a, c, 
e, g) show that the proportion of astrocytes that express MAPT was 
remarkably similar (~ 1/4th of astrocytes evaluated express MAPT 
transcript) in all three studies. Among the astrocytes that expressed 
any MAPT (b, d, f), the amount of MAPT transcripts detected in 
astrocytes was approximately the same as in neurons in the same 
brains. In AD astrocytes that express MAPT (f), the level of MAPT 
transcripts detected was higher than in MAPT expressing control 
astrocytes
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The single-cell and single-nucleus RNAseq studies were 
not informative about how the spatial localization of the 
astrocytes corresponded with MAPT expression. We also 
do not know if astrocytes upregulate MAPT when they 
become reactive. Neurodegenerative disease can increase 
astrocytic MAPT expression, suggesting that reactive 
astrogliosis could lead to astrocytes making more tau. 
However, the proportion of astrocytes that expressed 
MAPT didn’t increase with AD, indicating heterogeneity 
in astrocytes throughout healthy and diseased states. In 
summary, much remains unknown about MAPT expres-
sion in astrocytes including the basis for spatial heteroge-
neity of the MAPT expression.
Phosphorylation of tau is a widely studied tau post-
translational modification, and the pattern of phospho-
specific epitopes expressed by ARTAG cells has been 
characterized [29, 43, 67]. Reactive astrocytes increase 
expression of some kinases [68, 69]. For instance, the 
mitogen-activated protein kinase (MAPK) are activated 
by stress, damage associated molecular patterns, and 
cytokines, and are known to be important pathways 
driving neuroinflammation and glial activation [70]. 
The MAPKs, among others, can also phosphorylate tau. 
TSAs were positive for the active (phosphorylated) form 
for all three MAPK pathways (ERK, JNK, p38), as well as 
GSK3B [29]. Ferrer et  al. [67] completed phosphoprot-
eomics on three control brain samples and three ARTAG 
brain samples. Interestingly, GFAP and aquaporin 4 were 
highly phosphorylated. They also found additional evi-
dence for MAPK and cyclin-dependent kinases (CDKs) 
involvement from the phosphoproteomics [67]. These 
two studies imply that astrocyte activation may be driv-
ing high kinase activity in the astrocytes. This could be 
stimulating neuroinflammation, as well as phosphorylat-
ing tau. However, it has not yet been shown if the p-tau+ 
astrocytes express more kinase activity than the p-tau-
astrocytes in brains with ARTAG–NC.
While they may be in some senses “reactive” to local 
tissue injury or insult, p-tau+ astrocytes have less GFAP 
staining and are smaller than p-tau-astrocytes from 
healthy control brains; they also appear to be misshapen 
[67]. Schwab et al. [71] explored a link between TBI and 
markers of cellular senescence in astrocytes. Specifically, 
they asked if a history of repetitive TBI increased γH2AX, 
a marker of double strand DNA breaks, in astrocytes. The 
increase in γH2AX was found in ependymal and sube-
pendymal cells and subpial astrocytes. This study did not 
specifically evaluate ARTAG, however [71]. While evalu-
ation of white matter TSAs found the cells negative for 
ubiquitin, p62, beta-amyloid, and alpha-synuclein [29], 
perhaps suggesting that the astrocytopathy see was due 
specifically to tau misfolding. Of note, the p-tau+ astro-
cytes did express superoxide dismutase 2 (SOD2), and 
it was suggested that the SOD2 may be a cellular senes-
cence marker [29]. It is unclear whether SOD2 expression 
contributed to or was a downstream effect of abnormal 
tau inclusions in TSAs.
Another theme that emerges from human phenom-
enology is the presence of glial tau inclusions at bor-
der regions between micro-domains and at connection 
Fig. 8 Two hypothesis of ARTAG development. (a) In the neuronal centric model, a neuron expresses the majority of the tau protein (1). The neuron 
releases this tau protein (2) which (after trauma or axonal breakage) may be taken up by an astrocyte (3) during the glymphatic removal of the tau 
protein. This leads to the accumulation of exogenous tau, and the seeding of aggregated astrocyte tau. (b) In the astrocyte centric model, most 
healthy astrocytes express no or very low levels of MAPT. Changes in the brain environment—from an injury, aging, disease, or a combination 
of factors—leads to a reactive astrocyte response (1), which may be centered around small blood vessels (2, 3). The reactive astrocytes then 
upregulate the expression of MAPT and increase kinase activity (4), which leads to the hyperphosphorylation and aggregation of tau (5), causing 
p-tau + aggregates in astrocyte cell bodies and perivascular foot processes (6)
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points between cells. The molecular underpinnings of 
these observations are mostly unknown. Kovacs et  al. 
evaluated glial aquaporin-4 and Connexin-43 in ARTAG 
cases [72]. Aquaporin-4 is a water-channel protein, 
expressed at astrocyte “endfeet”, which plays an impor-
tant role in glymphatic function in the CNS [18]. Con-
nexin-43 is a major gap junction protein expressed by 
astrocytes [73]. In areas with high astrocyte p-tau stain-
ing, connexin-43 and aquaporin-4 staining was increased 
or remain highly expressed [72]. The study did not spe-
cifically test whether the cellular localizations of con-
nexin-43, and aquaporin-4 was altered. Overexpression 
and mis-localization of the proteins away from astrocytic 
endfeet might alter the physiological function of these 
proteins [18]. Further evaluation of these proteins and 
other endfeet proteins in ARTAG–NC is warranted.
Pathologic mechanisms
Some of the potential disease-driving paradigms linked 
to ARTAG–NC derive from prior studies focusing on 
neuronal tau pathology. A growing body of evidence 
demonstrates that tau paired helical filaments (PHF) 
can promote further aggregation of tau in an amplifying, 
feed-forward mechanism similar to, or at least analo-
gous to, prion diseases. In the nucleation-elongation 
mechanism, PHF tau “seeds” placed into the brain can 
initiate and accelerate more tau aggregation in an auto-
propagating manner [27, 74]. This mechanism was sup-
ported experimentally using in  vitro assays initially, but 
numerous studies have now demonstrated that pre-
formed aggregated tau or human diseased brain extracts 
can accelerate tau aggregation in various animal models 
[75–77]. Here we focus on the studies most relevant to 
ARTAG–NC.
Tau seeds have been isolated from human brains with 
multiple tauopathies, including glial tauopathies. When 
injected into a mouse brain, tau seeds lead to trans-syn-
aptic pathologic spreading that maintains the disease’s 
tau strain identity. For instance, AD tau extracts will 
seed neuronal tau, whereas PSP or CBD (human diseases 
with abundant glial tauopathy) brain extracts will seed 
glial tau [78]. In addition to the cell type specificity, the 
tau isoform from the diseased donor, be it 3R or 4R tau, 
were recapitulated in the recipient mouse: brain extracts 
from AD cases seeded 3R and 4R tau, while PSP and CBD 
brain extracts seeded 4R tau, and PiD seeded 3R tau [78, 
79]. These studies showed that there are disease-specific, 
cell type-specific, and, to some extent, isoform-specific 
mechanisms underlying tau seeds.
Narasimhan et  al. [80] asked if the formation of glia 
tau required neuronal tau. Using mice with a neuronal-
specific deletion of MAPT, they tested if CBD-tau or 
PSP-tau could induce glial tauopathy. They found that 
CBD-tau injected mice had tufted astrocytes, and the 
PSP-tau injected mice had coiled body inclusions in oli-
godendrocytes [80]. This underscores that glia can form 
tau inclusions in the absence of neuronal-sourced tau. 
This study did not generate an astrocyte-specific MAPT 
knockout mouse to show that the aggregated tau was 
from endogenous astrocyte tau as opposed to some other 
cellular source.
Ferrer et  al. [67] found evidence that ARTAG–NC 
derived tau seeds were unlike seeds sourced from other 
diseases, in that they did not maintain the disease phe-
notype. In this study, ARTAG–NC tau brain extracts 
injected in the mice resulted in p-tau in neurons, astro-
cytes, and oligodendrocytes. The tau did not maintain 
the 4R specificity, as the ARTAG–NC tau brain extracts 
seeded both 3R and 4R tau [67]. As ADNC is a common 
comorbidity with ARTAG–NC, there remains the pos-
sibility that the ARTAG–NC tau samples also contained 
some ADNC tau, and that the latter was biologically 
active in tau seeding experiments.
The mechanisms leading to ARTAG are poorly under-
stood. However, our review of the literature suggests two 
hypothetical models that are not mutually exclusive. In 
the first model, neuronal injury causes the release of tau 
protein seeds, which accumulate in astrocytes instead of 
(or perhaps while) being cleared from the brain (Fig. 8a) 
[3, 40]. This model assumes that the ARTAG–NC astro-
cytic p-tau is primarily of neuronal origin. As discussed 
above, ARTAG–NC is commonly seen in CNS border 
zones that are important for glymphatic removal of waste 
[3]. Hence astrocytes may take up tau released from cells, 
and the tau aggregates present in astrocytes may repre-
sent ingested remnants. A weakness of this hypothesis 
is that it does not explain why ARTAG tau pathology is 
exclusively composed of 4R tau.
A second hypothetical model proposes that brain 
injury, in combination with age, lead to a transforma-
tion of astrocytes in ways that promote ARTAG–NC. 
In this model (Fig.  8b), when astrocytes become reac-
tive, they increase their expression of MAPT and have 
high kinase activity. It is also possible that non-translated 
MAPT mRNA could be translated in times of stress. The 
increase in tau and high kinase activity cause hyperphos-
phorylation and aggregation of tau within tau+ astro-
cytes. This model assumes that astrocytes—or at least a 
subset of astrocytes—make their own tau. As discussed 
above, ~ 25% of the astrocytes in the human brain express 
MAPT transcripts according to RNAseq experiments. In 
brains with neurodegenerative disease, astrocytes that 
express MAPT do so at higher levels than control brain 
astrocytes [66]. Moreover, there are many brains with 
ARTAG–NC that lack substantial neuronal tau pathol-
ogy. Even in Case #2 in the present paper, we note that 
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the minimal tau pathology observed was in glial appear-
ing cells, within subependymal and perivascular micro-
domains. It is intriguing that this person, despite a very 
long-term lesion in the brain, albeit causing only mild 
mechanical stress, had minimal ARTAG–NC but also 
had undergone long-term treatment with strong anti-
inflammatory drugs, given the possible role(s) played by 
inflammatory mediators in tauopathy. However, the com-
plex medical histories of both these individuals under-
score the challenges of direct cause/effect inferences that 
can be derived from human studies.
The limited number of astrocytes expressing MAPT 
could help explain the selective vulnerability of specific 
populations of astrocytes to ARTAG–NC and the patchy 
nature of ARTAG–NC. With chronological age, astro-
cyte morphology and molecular signatures are altered 
compared to young healthy brains, and astrocytes in 
aged brain respond differently to a TBI than astrocytes in 
young brains [20]. Further studies are required to explore 
the astrocyte subpopulations that express MAPT and 
their responses to brain injury.
We conclude that long-term space occupying lesions 
that impose chronic mechanical stress on the brain (in 
the examples described here, arachnoid cysts) may con-
tribute to the development of ARTAG–NC in a stress 
dose-dependent manner. That is, while both cases dem-
onstrate ARTAG–NC changes, Case #2 with less destruc-
tive mechanical stress was associated with mild and 
localized ARTAG–NC changes, whereas Case #1 with 
a more severe mechanical stress injury was associated 
with widespread and severe ARTAG–NC changes. In 
this manner, the case reports presented and the litera-
ture review suggest that CNS trauma (chronic or acute 
mechanical stress) can drive ARTAG–NC-like pathology. 
The lesions’ morphologies and locations suggest that the 
ARTAG–NC-like brain changes following injury from 
mechanical stressors differs from that seen with neurode-
generative diseases. More work is required to test models 
of ARTAG–NC development and the possible interaction 
of seeding and tau aggregation models. Future work will 
also be needed to understand the normal physiological 
function of tau phosphorylation in astrocytes (if any), 
and how ARTAG–NC changes astrocyte physiology. 
As we learn more about ARTAG, we will gain a greater 
understanding of how astrocytes contribute to the long 
term sequelae of CNS trauma and age-related cognitive 
decline.
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